Aubry K, Labourey J L, Bessède J P, Tubiana-Mathieu N, Rigaud M
E.N.T. Department, University Hospital Center, 2 Avenue Martin Luther-King, 87000 Limoges, France.
Clin Med Oncol. 2008;2:27-35. Epub 2008 Jan 22.
Pharyngo-laryngeal tumors classified as T3-4, N0-3, M0, are conventionally treated by mutilating surgery (total (pharyngo)-laryngectomy). Neo-adjuvant chemotherapy with 5-FU/platinum salt can be proposed in an attempt to preserve the larynx. The level of the response to chemotherapy ranges from 36 to 54% of cases. Thus, a large number of patients receive chemotherapy that is ineffective and not free from adverse effects. Three main enzymes are involved in the metabolism of 5-FU: thymidylate synthase (TS), thymidylate phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD). Several studies suggest that a high level of expression of these three genes correlates with a poor clinical response to 5-FU. The main purpose of our study was to look for a correlation between the levels of expression of the genes for sensitivity to 5-FU (TS, TP, DPD) within the tumor and the clinical response observed after three courses of chemotherapy combining 5-FU/platinum salt in patients presenting with advanced cancer of the pharyngo-larynx.
This was a prospective genetic study that had required approval from the Ethics Committee. The main assessment criterion was based on the assessment of the clinical response by an ENT panendoscopy and a cervical CT scan, after three courses of chemotherapy. The expression of the genes was determined by quantitative RT-PCR, using total RNA extracted from tumor biopsies taken during the initial panendoscopy.
The means calculated, in our study, for the three genes of interest (TS, TP, DPD) were lower in the responder group than those in the non-responder group.
Our preliminary findings reveal trends that confirm the hypothesis that the lower the level of expression of the sensitivity genes, the better the clinical response to chemotherapy. They now form part of a larger study that is currently in progress.
传统上,被归类为T3 - 4、N0 - 3、M0的咽喉部肿瘤采用毁损性手术(全(咽)喉切除术)进行治疗。可尝试采用5 - 氟尿嘧啶/铂盐进行新辅助化疗以保留喉部。化疗的有效率在36%至54%之间。因此,大量患者接受了无效且有不良反应的化疗。5 - 氟尿嘧啶的代谢涉及三种主要酶:胸苷酸合成酶(TS)、胸苷酸磷酸化酶(TP)和二氢嘧啶脱氢酶(DPD)。多项研究表明,这三种基因的高表达与对5 - 氟尿嘧啶的临床反应不佳相关。我们研究的主要目的是寻找晚期咽喉部癌患者肿瘤内5 - 氟尿嘧啶敏感性基因(TS、TP、DPD)的表达水平与5 - 氟尿嘧啶/铂盐联合化疗三个疗程后观察到的临床反应之间的相关性。
这是一项前瞻性基因研究,已获得伦理委员会批准。主要评估标准基于三个疗程化疗后通过耳鼻喉科全景内镜检查和颈部CT扫描对临床反应的评估。使用在初次全景内镜检查期间采集的肿瘤活检组织提取的总RNA,通过定量逆转录聚合酶链反应(RT - PCR)测定基因表达。
在我们的研究中,所关注的三个基因(TS、TP、DPD)在反应组中的计算均值低于无反应组。
我们的初步研究结果揭示了一些趋势,证实了敏感性基因表达水平越低,化疗临床反应越好这一假设。这些结果现在是正在进行的一项更大规模研究的一部分。